Bild

Leveraging the natural tolerance induction capabilities of the liver

Topas Therapeutics is focused on developing products to address areas of major unmet need, including autoimmune diseases, allergies and anti-drug antibodies. Topas’ technology platform induces antigen-specific immune tolerance by utilizing the liver’s natural immunology capabilities, targeting liver sinusoidal endothelial cells (LSECs), which generate tolerance against bloodborne antigens. Topas Particle Conjugates mimic such bloodborne antigens and follow their natural processing in LSECs, including the generation of long-lasting antigen-specific regulatory T cells (Tregs), a critically important type of immune cell for maintaining immune tolerance. Topas’ novel technology is enabling the development of new therapeutic solutions for challenging diseases.

Latest News

2020-10-19 – Press release

Topas Therapeutics Raises €22 Million (~USD 26 Million) in Series B Financing

read more …

2020-10-19 – Press release

Topas Therapeutics Appoints Klaus Martin, Ph.D. as Chief Executive Officer

read more …

2019-12-18 – Press release

Topas Therapeutics Announces First Patient Enrolled in Phase 1 Trial with TPM203 in Pemphigus Vulgaris

read more …

2019-03-20 – Press release

Topas Therapeutics to Participate at Upcoming Industry and Scientific Conferences

read more …

2018-09-27 – Press release

Topas Therapeutics to Participate at Upcoming Industry and Scientific Events

read more …